Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic Mice-Reference-Cited by-同舟云学术

Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic Mice

Published:2022-03-23 Issue:6 Volume:96 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Wong Ting Y.¹²,Horspool Alexander M.¹²^ORCID,Russ Brynnan P.¹²,Ye Chengjin³,Lee Katherine S.¹²,Winters Michael T.¹,Bevere Justin R.¹²,Miller Olivia A.¹²,Rader Nathaniel A.¹²,Cooper Melissa¹²,Kieffer Theodore⁴,Sourimant Julien⁵^ORCID,Greninger Alexander L.⁶^ORCID,Plemper Richard K.⁵,Denvir James⁷,Cyphert Holly A.⁸,Barbier Mariette¹²^ORCID,Torrelles Jordi B.³,Martinez Ivan¹⁹,Martinez-Sobrido Luis³^ORCID,Damron F. Heath¹²^ORCID

Affiliation:

1. Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, West Virginia, USA

2. Vaccine Development Center at West, Virginia University Health Sciences Center, Morgantown, West Virginia, USA

3. Host-Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute, San Antonio, Texas, USA

4. Department of Pathology, Anatomy and Laboratory Medicine, West Virginia University School of Medicine, Morgantown, West Virginia, USA

5. Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA

6. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA

7. Department of Biomedical Sciences, Marshall University, Huntington, West Virginia, USA

8. Department of Biological Sciences, Marshall University, Huntington, West Virginia, USA

9. West Virginia University Cancer Institute, Morgantown, West Virginia, USA

Abstract

Emerging SARS-CoV-2 VoC are posing new problems regarding vaccine and monoclonal antibody efficacy. To better understand immune evasion tactics of the VoC, we utilized passive immunization to study the effect of early-pandemic SARS-CoV-2 HCP against, Alpha, Beta, and Delta VoC.

Funder

WV High Education Policy Commission

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/jvi.02184-21

Reference71 articles.

1. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

2. SARS-CoV-2 genomic variations associated with mortality rate of COVID-19

3. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

4. Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, Connor T, Peacock T, Robertson DL, Volz E. 2020. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations COVID-19 Genomics Consortium UK (CoG-UK). https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563

5. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa;Tegally H;medRxiv,2020

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influenza virus strains expressing SARS-CoV-2 receptor binding domain protein confer immunity in K18-hACE2 mice;Vaccine: X;2024-10

2. In vivo antiviral efficacy of LCTG-002, a pooled, purified human milk secretory IgA product, against SARS-CoV-2 in a murine model of COVID-19;Human Vaccines & Immunotherapeutics;2024-01-22

3. A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses;Nature Biomedical Engineering;2023-09-25

4. In Vivo Antiviral Efficacy of LCTG-002, a Pooled, Purified Human Milk Secretory IgA product, Against SARS-CoV-2 in a Murine Model of COVID-19;2023-08-28

5. Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice;Vaccine;2023-07